Aurobindo Pharma is one of the leading vertically integrated formulations & API manufacturing companies in the world. It has a strong R&D focus and has a multi-product portfolio with manufacturing facilities in several countries. The company operates diversified businesses, structured to deliver targeted healthcare solutions across geographies and therapeutic areas. Its core operations are built on strong, integrated capabilities, encompassing both APIs and finished products. The company is one of the leading API manufacturers, with expertise in process chemistry and having the advantage of large-scale production. It is recognised globally for high-quality, reliable and cost-effective supplies. Its API business caters to both internal needs and external client demand across multiple therapeutic areas, driving profitability and sustaining the growth of its formulations area.

Aurobindo Pharma major competitors are Glenmark Pharma, Alkem Laboratories, Abbott India, Glaxosmithkline Phar, Ipca Laboratories, Ajanta Pharma, Lupin.
Market Cap of Aurobindo Pharma is ₹64,449 Crs.
While the median market cap of its peers are ₹60,024 Crs.

Aurobindo Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Aurobindo Pharma is 4.64 and is ranked 8 out of its 8 competitors.